Key Highlights
- Net loss was USD 3.42 million, compared with USD 5.41 million.
- Loss per share was USD 0.14, against USD 0.25.
- Total operating expenses were USD 3.44 million, against USD 5.47 million.
- Cash and cash equivalents were USD 2.10 million at September 30.
Actuate Therapeutics (NASDAQ:ACTU) reported a third quarter 2026 net loss of USD 3,420,649, compared with USD 5,407,470 in the third quarter of 2025. Basic and diluted net loss per share attributable to common stockholders was USD 0.14, compared with USD 0.25.
Weighted-average shares of common stock outstanding were 24,222,586, compared with 21,394,965. The company reported the figures in its quarterly filing for the period ended September 30, 2026.
Operating Expenses
Research and development expenses were USD 1,811,601, compared with USD 2,177,922, and general and administrative expenses were USD 1,627,486, compared with USD 3,294,456. Total operating expenses were USD 3,439,087, compared with USD 5,472,378, and the loss from operations was equal to that amount in each period.
Interest income was USD 23,501, compared with USD 69,971, and total other income, net, was USD 18,438, compared with USD 64,908. Total share-based compensation was USD 970,824, compared with USD 1,800,614.
Nine-Month Results
For the nine months ended September 30, 2026, the net loss was USD 13,913,033, compared with USD 17,673,899, and the net loss per share was USD 0.58, compared with USD 0.88. Total operating expenses were USD 14,051,631, compared with USD 17,806,839.
Research and development expenses for the nine months were USD 6,443,670, compared with USD 8,163,046, and general and administrative expenses were USD 7,607,961, compared with USD 9,643,793. Interest income for the nine months was USD 153,786, compared with USD 148,128, and total share-based compensation was USD 3,667,982, compared with USD 4,504,986.
Balance Sheet and Cash Flow
Cash and cash equivalents were USD 2,101,816, compared with USD 13,159,423 at the prior Balance Sheet date, and prepaid Assets and other current assets were USD 546,246, compared with USD 483,996. Total current assets were USD 2,648,062, compared with USD 13,643,419.
Total assets were USD 3,218,781, compared with USD 14,035,910, and total liabilities were USD 4,027,747, compared with USD 6,111,907. Net cash used in Operating Activities for the nine months was USD 12,373,256, compared with USD 15,470,210.
The filing states that on November 28, 2025 the company entered into an at-the-market issuance sales agreement under which it may issue and sell, through two sales agents, up to USD 100 million of shares of common stock, with the agents receiving a commission of up to 3.0% of gross sales proceeds. The company may sell shares at its sole discretion by any method deemed an at-the-market offering under Rule 415, and the agents received customary indemnification rights. It also describes a committed Equity Facility entered into on March 27, 2025. Interest expense was USD 5,063 in each of the third quarters of 2026 and 2025, and USD 15,188 for the nine months. Prepaid assets and other current assets were USD 546,246, and the company presents deferred offering costs within its non-current assets.
Actuate Therapeutics Q3 2026 Earnings: Key Takeaways
Actuate Therapeutics reported a third quarter 2026 net loss of USD 3,420,649 and a loss per share of USD 0.14. Total operating expenses were USD 3,439,087, and cash and cash equivalents were USD 2,101,816.
_11_16_2026_19_56_26_124029.jpg)





Please wait processing your request...